Tirzepatide vs Retatrutide
Dual versus triple agonism. The question is what glucagon receptor activation adds beyond incretin signaling.
Metabolic
Tirzepatide
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
Metabolic
Retatrutide
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
Side by side
| Dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Molecular weight | 4813.45 g/mol | 4731.32 g/mol |
| Size class | long peptide | long peptide |
| CAS number | 2023788-19-2 | 2381089-83-2 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 10mg, 20mg, 30mg | 10mg, 20mg, 30mg |
| Entry price | $89 | $99 |
| Cost per mg | $6.63 | $7.47 |
Mechanism
Tirzepatide
Tirzepatide is a synthetic 39-amino-acid peptide engineered from the native GIP sequence with structural modifications conferring agonism at both the GIP and GLP-1 receptors. A C20 fatty diacid moiety supports albumin binding and extended half-life. Its research interest lies substantially in the question of whether dual incretin agonism produces effects distinguishable from GLP-1 monoagonism.
Retatrutide
Retatrutide is a single-molecule triple agonist acting at the GIP, GLP-1, and glucagon receptors. The inclusion of glucagon receptor agonism is mechanistically distinct from dual agonists: glucagon receptor activation is studied for effects on hepatic lipid handling and energy expenditure, pathways not engaged by incretin agonism alone. It remains investigational and is a frequent subject of comparative receptor-pharmacology work.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
Tirzepatide
Evidence base: strong receptor-level characterization and independent replication; GIP receptor directionality remains genuinely contested.
Full research reference →Retatrutide
Evidence base: emerging. Receptor pharmacology characterized; long-term and independent replication limited by the compound's investigational status.
Full research reference →Research applications
Tirzepatide
- Dual incretin receptor signaling and biased agonism studies
- Comparative studies against selective GLP-1 agonists
- cAMP accumulation and β-arrestin recruitment assays
- Adipose and hepatic metabolic pathway research
Retatrutide
- Triple receptor agonism and pathway-contribution studies
- Hepatic lipid metabolism research in preclinical models
- Energy expenditure and thermogenesis pathway assays
- Head-to-head comparison against dual agonists
Common questions
What is the difference between Tirzepatide and Retatrutide?
Tirzepatide is dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity. Retatrutide is triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research. They differ in molecular weight (4813.45 vs 4731.32 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, Tirzepatide or Retatrutide?
Tirzepatide is lower at approximately $6.63 per milligram at its best tier, against $7.47 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can Tirzepatide and Retatrutide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should Tirzepatide and Retatrutide be stored?
Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days. For Retatrutide: Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Which has the stronger evidence base?
Tirzepatide — Evidence base: strong receptor-level characterization and independent replication; GIP receptor directionality remains genuinely contested. Retatrutide — Evidence base: emerging. Receptor pharmacology characterized; long-term and independent replication limited by the compound's investigational status.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.
Comparison generated from NuVida Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.